Today, as we take time to give thanks, we want to express our heartfelt gratitude to the patients and families who inspire our mission every day. Together, we’re advancing innovation to bring forward better treatment options -- and we’re humbled by the opportunity to make a difference. Wishing our community a warm and joyful Thanksgiving!
About us
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced program is focused on STAT6 (signal transducer and activator of transcription 6) where abnormal activation is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria. The company has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company.
- Website
-
http://www.recludixpharma.com
External link for Recludix Pharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Privately Held
Employees at Recludix Pharma
Updates
-
Today is National #STEM / #STEAM day, which encourages education and skills in the fields of science, technology, engineering, arts and mathematics. On this day, we’re taking a moment to recognize our remarkable interns, such as Miriam Garcia. Thank you for your valuable contributions, enthusiasm, and dedication -- your hard work has truly made a difference!
-
-
We’re making the rounds on the East Coast – this time in New York for the Stifel 2025 Healthcare Conference. If you are attending, be sure to catch our presentation on Tuesday, November 11th, which will be given by our President and CEO Nancy Whiting and CSO Brian Hodous. A webcast of our presentation will be available on our website: https://lnkd.in/gidksMyd
-
-
Our President and CEO Nancy Whiting and CSO Brian Hodous are taking the stage at the Guggenheim Annual Healthcare Innovation Conference in Boston. Join us at our presentation on Monday, November 10th as we share the latest developments from our pipeline of SH2-domain targeted therapies, including our lead oral STAT6 inhibitor. The webcast will be accessible on our website: https://lnkd.in/gidksMyd
-
-
Catch our CBO Matthew Caldemeyer at #BIOEurope to hear more about how we are rapidly advancing our STAT6 inhibitor towards an IND filing and into the clinic, the progress being made on our SH2-domain targeted BTK inhibitor, as well as our discovery pipeline of other high value targets where targeting the SH2 domain can prove differentiating.
Excited to attend #BIOEurope—THE life science partnering event of the year with 5,700+ attendees! Register by July 25 to save up to €1,500. https://lnkd.in/gUhZ2Tgm. Please reach out to me to connect at the conference! Informa Connect
-
-
Eczema refers to a series of skin conditions, such as atopic dermatitis, and impacts more than 31 million people in the U.S. These types of allergic diseases are driven by inflammatory mediators called cytokines. We are advancing an oral, selective STAT6 inhibitor into clinical development, as STAT6 is crucial for the signaling of key cytokines in these diseases. More information on eczema can be found from: the Cleveland Clinic at https://lnkd.in/g78KgciB; American College of Allergy, Asthma & Immunology at https://lnkd.in/eM-Rxe7t; and the Allergy & Asthma Network at https://lnkd.in/ecgsXwka
-
-
Aloha from San Diego! We may have brought the island vibes to our employee picnic this year, but Team Recludix brought the fun! We came together and celebrated another productive year with brain freezes from the Kona Ice Truck, fun transformations at the face painting station, and most importantly lots of camaraderie!
-
-
Join us virtually for the Stifel 2025 Virtual Immunology and Inflammation Forum to hear the latest updates from our President and CEO Nancy Whiting, Head of R&D Ajay Nirula, and CSO Brian Hodous. Our presentation on September 16th will review the exciting progress we’re making on the development of oral SH2 domain inhibitors for the treatment of inflammatory disease. A live and archived webcast of the presentation can be found on our website: https://lnkd.in/gidksMyd
-
-
Our President and CEO Nancy Whiting and Head of R&D Ajay Nirula will be in New York for the Cantor Global Healthcare Conference on September 4th. If you would like to connect with them on our portfolio of innovative, oral SH2 domain-targeted inhibitors, including STAT6 and BTK inhibitors, you can reach us via: https://lnkd.in/eF56CSgp
-
-
At Recludix, we are proud to have a woman CEO, a woman BOD chair, and incredibly talented women throughout our company. On #WomensEqualityDay, we are reminded to celebrate the multifaceted leadership of women, such as their enduring contributions to innovation and their profound influence as driving forces within organizations and society.
-